Bausch Health/$BHC
1D1W1MYTD1Y5YMAX
Capital at risk
About Bausch Health
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
- Ticker
- $BHC
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 20,300
- Headquarters
- Laval, Canada
- Website
- www.bauschhealth.com
Bausch Health Metrics
BasicAdvanced
$2.1B
-
-$2.99
0.38
-
Price and volume
Market cap
$2.1B
Beta
0.38
52-week high
$8.00
52-week low
$4.33
Average daily volume
2.7M
Financial strength
Current ratio
1.435
Quick ratio
0.9
Long term debt to equity
-24.81
Total debt to equity
-19.219
Interest coverage (TTM)
1.66%
Profitability
EBITDA (TTM)
3,854
Gross margin (TTM)
71.82%
Net profit margin (TTM)
-10.12%
Operating margin (TTM)
25.21%
Effective tax rate (TTM)
-49.32%
Revenue per employee (TTM)
$530,000
Management effectiveness
Return on assets (TTM)
6.57%
Return on equity (TTM)
333.74%
Valuation
Price to revenue (TTM)
0.195
Price to book
-1.03
Price to tangible book (TTM)
-0.13
Price to free cash flow (TTM)
1.517
Free cash flow yield (TTM)
65.92%
Free cash flow per share (TTM)
3.738
Growth
Revenue change (TTM)
10.09%
Earnings per share change (TTM)
-1,225.87%
3-year revenue growth (CAGR)
9.13%
10-year revenue growth (CAGR)
0.49%
3-year earnings per share growth (CAGR)
79.86%
10-year earnings per share growth (CAGR)
0.04%
What the Analysts think about Bausch Health
Analyst ratings (Buy, Hold, Sell) for Bausch Health stock.
Analyst projections of the future price of Bausch Health stock.
Bulls say / Bears say
Bausch Health surged on a Q2 earnings beat, reporting adjusted EPS of $1.26 (up 40% YoY) and consolidated revenue of $2.85 billion (up 13%), and subsequently raised full-year guidance. (Investing.com)
Strong performance in high-margin Salix gastrointestinal and Solta aesthetic segments drove revenue and earnings ahead of Wall Street forecasts in Q2. (Investing.com)
Excluding Bausch + Lomb, Bausch Health delivered its 13th consecutive quarter of year-over-year organic revenue and adjusted EBITDA growth, underscoring the resiliency of its specialty pharma portfolio. (Investing.com)
Despite a $434 million reduction in Q2, Bausch Health still carries an elevated net debt balance of $13.7 billion and bears a weighted average interest rate of 7.52%, which could strain cash flow amid higher rates. (Motley Fool) (SEC)
The company cautioned that second-half headwinds, including generic competition for its Aplenzin antidepressant and pricing pressures under Medicaid and 340B programs, may erode margins going forward. (Investing.com)
Xifaxan®, one of Bausch Health’s top gastrointestinal products, has been selected for Medicare price negotiation under the Inflation Reduction Act with negotiated prices effective January 1, 2027, which is expected to meaningfully reduce its revenue from 2027 onward. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 26 Aug 2026.
Bausch Health Financial Performance
Revenues and expenses
Bausch Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Bausch Health News
AllArticlesVideos
Funds containing Bausch Health
AllUSDEURGBP
Fund name | Fund size | $BHC weighting |
|---|---|---|
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI World Small Cap£WLDS | £6.7B | 0.01% |
Vanguard ESG Global All Cap£V3AB | £905M | 0.00% |
Vanguard ESG Global All Cap€V3AA | €1.1B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.